Lecture
LED3 Lecture: GLP-1 receptor agonists: state of the art and the newest insights
- Lotte Bjerre Knudsen (Novo Nordisk, DK)
- Date
- Thursday 27 November 2025
- Time
- Location
-
Gorlaeus Building
Einsteinweg 55
2333 CC Leiden - Room
- BM.1.33
About Lotte Bjerre Knudsen
Lotte Bjerre Knudsen holds a degree in biotechnology from the Technical University of Denmark and a Doctoral degree in Scientific Medicine from the University of Copenhagen, Denmark. Lotte has been with Novo Nordisk since her university graduation in 1989 and has since then held several positions within the company and is today Chief Scientific Advisor in Research & Early Development. She has deep experience across the entire value chain of drug discovery and development and has published extensively. Lotte is an inventor on many patents, all fully owned by Novo Nordisk. Specifically, to the area of GLP-1, Lotte is a co-inventor of liraglutide and has led all biology research programs for liraglutide and semaglutide from diabetes to obesity, cardiovascular, kidney and Alzheimer’s Disease. She has been part of representing Novo Nordisk in five FDA Advisory committees. In honor of her work Lotte has also received numerous awards including: the Breakthrough Prize in Life Sciences (2025), the Lasker Award in clinical research (2024), the Golden Plate Award of the American Academy of Achievement (2024), the Mani L. Bhaumik Breakthrough of the Year Award (2024), the Danish Biotech Life-Time Achievement Award (2023), the Paul Langerhans Award from the German Diabetes Association (2023), and the STAT Biomedical Innovation Award (2023).